
Jan 12 (Reuters) - Medtronic has "significant firepower" to pursue acquisitions as the medical device maker evaluates opportunities to expand its portfolio, executives said at a major industry conference that kicked off on Monday in San Francisco.
The medical device maker has been eyeing tuck-in deals as it seeks to diversify its portfolio, particularly in cardiology and neuroscience, with CEO Geoff Martha in November saying that they would prefer companies in "early stage or close to market."
The company's balance sheet gives it flexibility to execute a "meaningful number" of transactions without financial strain, Chief Financial Officer Thierry Piéton said at the J.P. Morgan healthcare conference on Monday.
"What's changing versus the last few years is coming back to doing more M&A," he said, adding that Medtronic's dividend policy remains unchanged.
Medtronic, which makes devices ranging from pacemakers to insulin pumps, reported a 3.7% rise in revenue to $33.6 billion in fiscal 2025.
The company is targeting deals in the low- to mid-single-digit billions of dollars, choosing targets that will supplement its internal R&D efforts, Martha said on Monday. The company has set up a new committee at the board level to move faster on deals, he added.
The executives said Medtronic is focused on two themes, expanding in areas where it already competes and acquiring enabling technologies for procedures such as cardiac ablation and surgical robotics.
The company has spent recent years improving operations by divesting non-core units and plans to spin off its diabetes business as MiniMed Group through a U.S. initial public offering following its struggles over the last few years.
It also added two new directors to its board last year after activist investor Elliott Investment Management emerged as one of its largest shareholders.
Medtronic now sees itself positioned to pursue strategic opportunities.
"We've earned the right to do these acquisition, and we've got the capacity, so we're going to step up," Piéton said.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Alan Barona and Leroy Leo)
latest_posts
- 1
AstraZeneca to acquire Modella AI to speed oncology drug research - 2
Disability rights activist and author Alice Wong dies at 51 - 3
‘Trip of suffering’: Gaza evacuee details 24-hour journey to South Africa - 4
German police 'cleared path for fascists with batons,' protesters say - 5
African nations push to recognize crimes of colonialism in Algeria
Interstellar comet 3I/ATLAS will fly by Earth Friday. Here are the latest images
UN experts urge investigation into Israel’s killing of Lebanese journalists
The Main 20 Gaming Control center Ever
Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
Tech Development Disclosed: A Survey of \Usefulness and Configuration in Concentration\ Tech Item
Figure out how to Put resources into Lab Precious stones: A Novice's Aide
Alleged maple syrup scam in Quebec uncovered by Canadian broadcaster
A Manual for Well known Western television Series
New COVID-19 variant 'Cicada' is spreading. What to know about BA.3.2.













